Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study

The article discusses the effectiveness and persistence of golimumab (GLM) as a second-line treatment for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) in Italy. The study found that after 12 months of GLM treatment, a significant number of patients achieved low disease activity or minimal disease activity. The overall persistence rate at 12 months was high, indicating that GLM had a favorable benefit-risk profile and was well-tolerated by patients. The study also found improvements in disease activity measures and quality of life scores. These findings support the use of GLM as a second-line treatment option for these conditions. [Extracted from the article]